Category: Ability

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

September 15, 2024

•

Investor Empires

Article Content Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development. Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials. BOSTON, Sept. 15, 2024…
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

September 15, 2024

•

Investor Empires

Article Content Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development. Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials. BOSTON, Sept. 15, 2024…
Experts Confident in Bitcoin’s Ability to Defend $60K Despite Bearish Pressure

June 28, 2024

•

Investor Empires

Bitcoin has seen a decline of more than 6% over the past week. Successive corrections have temporarily pushed the asset below $60,000. Although it has rebounded since then, its recovery appears to have stalled at around $61,500, causing investors to worry about further losses. This is especially true as the…

Category: Ability

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Experts Confident in Bitcoin’s Ability to Defend $60K Despite Bearish Pressure